These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39015093)

  • 1. Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective.
    Clarke K; Ainslie-Garcia M; Ferko N; Shastri K
    J Med Econ; 2024; 27(1):952-962. PubMed ID: 39015093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
    Jha A; Upton A; Dunlop WC; Akehurst R
    Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
    Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
    Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim.
    McBride A; Wang W; Campbell K; Balu S; MacDonald K; Abraham I
    J Med Econ; 2020 Aug; 23(8):856-863. PubMed ID: 32323582
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis.
    Peng K; Chan SCW; Wang Y; Cheng FWT; Yeung WWY; Jiao Y; Chan EWY; Wong ICK; Lau CS; Li X
    JAMA Netw Open; 2024 Jun; 7(6):e2418800. PubMed ID: 38922614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact analysis of biosimilar natalizumab in the US.
    Li E; Goh A; Gupta S; Schauf M; Chen A; Hartung DM
    Am J Manag Care; 2024 Jul; 30(7):e191-e197. PubMed ID: 38995822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs.
    Reese R; Nanavath SR; Martin J; Travers JB; Rohan CA
    J Dermatolog Treat; 2024 Dec; 35(1):2402912. PubMed ID: 39278830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database.
    Stajszczyk M; Obarska I; Jeka S; Batko B
    Ann Rheum Dis; 2023 Sep; 82(9):1171-1180. PubMed ID: 37328194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
    Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
    Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.
    Aladul MI; Fitzpatrick RW; Chapman SR
    Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
    Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
    Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic impact of etanercept and adalimumab biosimilars on hospitals scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products].
    Berreur B; Guerin F; Christophe B; Limido G; Paubel P
    Ann Pharm Fr; 2018 Jan; 76(1):57-63. PubMed ID: 29180236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
    Cesarec A; Likić R
    Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer.
    MacDonald K; Alrawashdh N; McBride A; Abraham I
    Future Oncol; 2021 Nov; 17(33):4561-4570. PubMed ID: 34382416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Access to biologicals in Crohn's disease in ten European countries.
    Péntek M; Lakatos PL; Oorsprong T; Gulácsi L; Pavlova M; Groot W; Rencz F; Brodszky V; Baji P; Crohn's Disease Research Group
    World J Gastroenterol; 2017 Sep; 23(34):6294-6305. PubMed ID: 28974896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
    Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
    Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
    Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.